Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

26th EORTC-NCI-AACR Symposium

Highlights of the EORTC-NCI-AACR Symposium

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

Highlights of the EORTC-NCI-AACR Symposium ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Predicting the relapse of acute myeloid leukaemia with genetic screening

Dr Elaine Mardis - University of Washington, Washington, USA

Predicting the relapse of acute myeloid leukaemia with genetic screening ( Dr Elaine Mardis - University of Washington, Washington, USA )

Choosing personalised treatment options based on molecular evidence

Dr Funda Meric-Bernstam - MD Anderson Cancer Centre, Houston, USA

Choosing personalised treatment options based on molecular evidence ( Dr Funda Meric-Bernstam - MD Anderson Cancer Centre, Houston, USA )

Frontiers of pharmacokinetics and metabolism in cancer research

Prof Godefridus Peters - VU University Medical Center, Amsterdam, Netherlands

Frontiers of pharmacokinetics and metabolism in cancer research ( Prof Godefridus Peters - VU University Medical Center, Amsterdam, Netherlands )

Biomarker for PARP inhibitor responsiveness in ovarian cancer patients

Prof Elizabeth Swisher - University of Washington, Washington, USA

Biomarker for PARP inhibitor responsiveness in ovarian cancer patients ( Prof Elizabeth Swisher - University of Washington, Washington, USA )

Overcoming cancer resistance with enzyme inhibitors

Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden

Overcoming cancer resistance with enzyme inhibitors ( Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden )

New drug, ASP8273, shows response in Japanese patients with treatment-resistant...

Dr Haruyasu Murakami - Shizuoka Cancer Center, Shizuoka, Japan

New drug, ASP8273, shows response in Japanese patients with treatment-resistant non-small cell lung cancer ( Dr Haruyasu Murakami - Shizuoka Cancer Center, Shizuoka, Japan )

The work and aims of SPECTA for better clinical trials

Dr Vassilis Golfinopoulos - European Organization for Research and Treatment of...

The work and aims of SPECTA for better clinical trials ( Dr Vassilis Golfinopoulos - European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium )

More from ecancer